Covered recipient · General Payments record
BRIAN FOSTER RABINOWITZ
Allopathic & Osteopathic Physicians Pediatrics
General Payments · PY2018–2024
$2,387.13
- Reported across 108 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $342.42 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $104.79 | 6 |
| Verrica Pharmaceuticals Inc. | $67.17 | 3 |
| Merck Sharp & Dohme Corporation | $63.80 | 3 |
| Seqirus USA Inc | $44.48 | 2 |
| Kaleo, Inc. | $43.77 | 2 |
| IRONWOOD PHARMACEUTICALS, INC | $18.41 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| IRONWOOD PHARMACEUTICALS, INC | $18.41 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153749115 | CMS |
| kaleo, Inc. | $21.56 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126623294 | CMS |
| kaleo, Inc. | $22.21 | 07/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126623296 | CMS |
| Merck Sharp & Dohme LLC | $25.32 | 01/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141712055 | CMS |
| Merck Sharp & Dohme LLC | $17.27 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141712045 | CMS |
| Merck Sharp & Dohme LLC | $21.21 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141872869 | CMS |
| PFIZER INC. | $15.16 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131102978 | CMS |
| PFIZER INC. | $16.09 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131044840 | CMS |
| PFIZER INC. | $16.83 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131507251 | CMS |
| PFIZER INC. | $17.24 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131752170 | CMS |
| PFIZER INC. | $17.06 | 09/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131397142 | CMS |
| PFIZER INC. | $22.41 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132087186 | CMS |
| Seqirus USA Inc | $18.20 | 01/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125634677 | CMS |
| Seqirus USA Inc | $26.28 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125634679 | CMS |
| Verrica Pharmaceuticals Inc. | $23.66 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118385552 | CMS |
| Verrica Pharmaceuticals Inc. | $20.97 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118385554 | CMS |
| Verrica Pharmaceuticals Inc. | $22.54 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118385556 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.